COVID-19 vaccine: SII plans to conduct bridging trial for Novavax's candidate in Feb, says CEO1 min read . Updated: 14 Jan 2021, 03:55 PM IST
- The world’s biggest vaccine maker will start stockpiling millions of doses of the Novavax coronavirus vaccine candidate starting around April, said CEO
The Serum Institute of India will try to conduct the bridging trial for Novavax's COVID-19 vaccine candidate in India in February, said CEO Adar Poonawalla on Thursday. Bridging trial is a supplementary trial performed in a new region or country to get more clinical data on efficacy, safety and dose regimen.
Select your Category